JCA Pulse › Countries
JCA by countryEU JCA by country: 31 European markets
Who leads each joint clinical assessment, and where national HTA has started.
How each of 31 European markets is involved in current joint clinical assessments: as the assessor or co-assessor that leads a JCA, and where a national HTA record already exists. 16 countries currently lead or co-lead at least one assessment.
None yet12–34–67 or moreLeads or co-leads a JCA
Each number counts assessor and co-assessor roles plus national HTA records for technologies in JCA Pulse.
Country by country
Germany 16 links to current JCAs
- Assessor
- Cosibelimab, Daraxonrasib, Fuzuloparib, Lunsotogene parvec, Mezigdomide, Senaparib, Tarlatamab, Lurbinectedin, Sintilimab
- Co-assessor
- Taletrectinib, Tovorafenib
- National records
- CamizestrantNot started · TovorafenibAssessing · TarlatamabAssessing · LurbinectedinAssessing · Onasemnogene abeparvovec, intrathecalAssessing
Sweden 10 links to current JCAs
- Assessor
- Bifikafusp alfa / onfekafusp alfa, Lirafugratinib, Taletrectinib, Catequentinib
- Co-assessor
- Relacorilant, Sonrotoclax
- National records
- CamizestrantNot started · TarlatamabAwaiting · LurbinectedinAwaiting · Onasemnogene abeparvovec, intrathecalAwaiting
France 9 links to current JCAs
- Assessor
- Autologous bioengineered skin substitute, HighLife trans-septal mitral valve replacement system, Autologous TIL
- Co-assessor
- Cosibelimab, Onasemnogene abeparvovec, intrathecal
- National records
- SAPIEN M3 transcatheter mitral valve replacement systemAssessing · TovorafenibAccess · TarlatamabAccess · LurbinectedinAwaiting
Netherlands 9 links to current JCAs
- Assessor
- Rezvilutamide, Zamtocabtagene autoleucel, SAPIEN M3 transcatheter mitral valve replacement system, Sasanlimab
- Co-assessor
- Fuzuloparib
- National records
- TovorafenibAwaiting · TarlatamabAwaiting · LurbinectedinAwaiting · Onasemnogene abeparvovec, intrathecalAwaiting
United Kingdom 8 links to current JCAs
- National records
- CamizestrantNot started · MezigdomideNot started · SonrotoclaxNot funded · TaletrectinibAssessing · TovorafenibAssessing · TarlatamabAssessing · LurbinectedinNot funded · Onasemnogene abeparvovec, intrathecalAssessing
Austria 7 links to current JCAs
- Assessor
- Camizestrant, Ensartinib, Rebisufligene etisparvovec
- Co-assessor
- Lirafugratinib, Zopapogene imadenovec
- National records
- TarlatamabAssessing · LurbinectedinAssessing
Norway 7 links to current JCAs
- Assessor
- Pelabresib
- Co-assessor
- Lunsotogene parvec, SAPIEN M3 transcatheter mitral valve replacement system, Catequentinib
- National records
- TarlatamabAssessing · LurbinectedinAssessing · Onasemnogene abeparvovec, intrathecalAssessing
Ireland 6 links to current JCAs
- Assessor
- Tovorafenib, Onasemnogene abeparvovec, intrathecal
- Co-assessor
- Rezvilutamide, Zamtocabtagene autoleucel
- National records
- TarlatamabAssessing · Onasemnogene abeparvovec, intrathecalNegotiating
Denmark 5 links to current JCAs
- Assessor
- Zopapogene imadenovec
- Co-assessor
- Daraxonrasib, Sasanlimab
- National records
- TarlatamabAssessing · LurbinectedinAssessing
Belgium 4 links to current JCAs
- Assessor
- Sonrotoclax
- Co-assessor
- Autologous bioengineered skin substitute, Camizestrant
- National records
- LurbinectedinAccess
Poland 4 links to current JCAs
Hungary 2 links to current JCAs
- Co-assessor
- Rebisufligene etisparvovec, Tarlatamab
Portugal 2 links to current JCAs
- Assessor
- Relacorilant
- Co-assessor
- Lurbinectedin
Spain 2 links to current JCAs
- Co-assessor
- Ensartinib
- National records
- LurbinectedinNot started
Estonia 1 link to current JCAs
- Co-assessor
- Pelabresib
Slovakia 1 link to current JCAs
- Co-assessor
- Sintilimab
Slovenia 1 link to current JCAs
- Co-assessor
- Senaparib
No current JCA roles or national records: Bulgaria, Croatia, Cyprus, Czechia, Finland, Greece, Iceland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Romania.
JCA Pulse Pro
The national translator
What each JCA means for the national route, price and timing in all 31 markets, with Evidaxia’s outlook.
Explore Pro